The global gastrointestinal stromal tumor (GIST) therapeutics market is expected to garner a market value of USD 890 Million in 2023 and is expected to accumulate a market value of USD 1593 Million by registering a CAGR of 6% in the forecast period 2023 to 2033.
Growth of the gastrointestinal stromal tumor (GIST) therapeutics market can be attributed to growing prevalence of GIST in the aging population across the globe. The market for gastrointestinal stromal tumor (GIST) therapeutics registered a CAGR of 3.5% in the historical period 2018 to 2022
Gastrointestinal Stromal Tumor (GIST) Therapeutics refers to the medical treatments used to manage GIST, a type of cancer that occurs in the cells of the gastrointestinal tract. The goal of GIST therapeutics is to control or eliminate the cancer cells and reduce symptoms.
The treatment options for GIST include surgery, targeted therapy with tyrosine kinase inhibitors (TKIs), radiation therapy, and chemotherapy. The choice of therapy depends on the size, location, and stage of the tumor, as well as the patient's overall health. The goal is to provide the most effective treatment while minimizing side effects.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 890 Million |
| Anticipated Forecast Value (2033) | USD 1593 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
According to market research and competitive intelligence provider Future Market Insights- the market for Gastrointestinal stromal tumor (GIST) therapeutics reflected a value of 3.5% during the historical period, 2018 to 2022.
The Gastrointestinal Stromal Tumor (GIST) Therapeutics Market was growing during the period from 2018 to 2022. The growth was primarily driven by the increasing incidence of gastrointestinal stromal tumors and the approval of new drugs for the treatment of GIST. In addition, the rising awareness about GIST and the availability of advanced therapies are also contributing to the growth of the market. However, the high cost of treatment and the limited number of approved drugs may hinder the growth of the market.
Thus, the market for Gastrointestinal stromal tumor (GIST) therapeutics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Demand for effective therapies driving growth for GIST therapeutics market
The incidence of GIST is increasing worldwide, which is driving the demand for effective treatment options. As GIST is a difficult cancer to treat, there remains a significant unmet medical need for new and effective therapies. Moreover, development of new technologies, such as tyrosine kinase inhibitors (TKIs), has led to improved treatment outcomes for patients with GIST.
Furthermore, increasing awareness about GIST and its treatment options, among healthcare providers and patients, is driving demand for GIST therapeutics. In addition, governments around the world are providing support for cancer research and drug development, which is helping to drive growth in the GIST therapeutics market.
Availability of various treatments creating lucrative opportunities for GIST therapeutics market
As GIST cannot be completely treated with surgery, the dependency on various therapeutics has increased. Moreover, healthcare professionals are suggesting different therapeutics methods that would cater to the condition of the patients.
Surgery: Surgical removal of the tumor is the primary treatment option for localized GISTs.
Imatinib: This is a tyrosine kinase inhibitor (TKI) that targets the KIT and PDGFRA genes that are often mutated in GISTs. Imatinib is the first-line therapy for advanced GISTs.
Sunitinib: This is another TKI that is used as a second-line treatment for patients who have developed resistance to imatinib.
Regorafenib: This is another TKI that is used as a third-line treatment for patients who have become resistant to both imatinib and sunitinib.
Radiation therapy: Radiation therapy may be used in conjunction with surgery or as palliative treatment for GISTs that cannot be surgically removed.
Chemotherapy: Chemotherapy is generally not effective in treating GISTs, but it may be used in combination with other therapies.
Lengthy approval process and drug resistance restricting market growth
The cost of GIST treatments, especially targeted therapies and other innovative drugs is high. This, in turn, limits access to these treatments for some patients. GIST is a relatively rare type of cancer, which means that the market for GIST therapeutics is smaller compared to other cancer indications.
As patents for GIST treatments expire, generic versions of these drugs may become available, which can decrease the market share and profitability of brand-name treatments. Some patients with GIST may develop resistance to TKIs, which can limit the effectiveness of these treatments over time.
The approval process for new drugs can be lengthy and expensive, and there is always the risk that a new treatment may not be approved by regulatory agencies. Some GIST treatments can cause adverse effects, such as nausea, vomiting, fatigue, and low blood counts, which can impact patient quality of life and limit the use of these treatments. All these factors are hampering the growth of the GIST market.
Introduction of new and innovative therapies creating lucrative opportunities for GIST therapeutics
The North American market for Gastrointestinal Stromal Tumor (GIST) therapeutics is one of the largest and most mature markets globally, driven by factors such as a large and aging patient population, high levels of healthcare spending, and a strong presence of pharmaceutical companies. The United States is the largest market for GIST therapeutics in North America, accounting for the majority of sales in the region.
In recent years, the North American market for GIST therapeutics has seen steady growth due to the increasing incidence of GIST, the introduction of new and innovative therapies, and growing demand for effective treatments. The availability of targeted therapies, such as tyrosine kinase inhibitors (TKIs), has been a major driver of growth in the market, as these drugs have proven to be highly effective in treating GIST. Thus, North America is expected to possess 39% market share for GIST therapeutics market in 2023.
Growing prevalence of GIST in aging population propelling market growth
The Asia Pacific market for gastrointestinal stromal tumor (GIST) therapeutics is a rapidly growing market, driven by factors such as increasing incidence of GIST, rising levels of healthcare spending, and a growing middle-class population. The market is expected to continue to grow in the coming years, driven by factors such as the increasing availability of targeted therapies, such as tyrosine kinase inhibitors (TKIs), and the growing awareness of GIST among healthcare providers and patients.
Despite these challenges, the Asia Pacific market for GIST therapeutics is expected to continue to grow in the coming years, driven by increasing demand for effective treatments, advances in research and development, and improving economic conditions in the region. The market is also likely to benefit from the growing aging population and the increasing incidence of GIST, which are expected to drive demand for GIST treatments in the future. Thus, Asia Pacific is expected to hold 31% market share for GIST therapeutics market in 2023.
Presence of innovative drugs and technology making hospitals a viable option for treatment of GIST therapeutics
Hospitals have a high level of expertise in treating complex and rare diseases such as GIST, and often have a dedicated team of specialists who are experienced in diagnosing and treating the condition. In addition, hospitals provide comprehensive care for GIST patients, including surgery, chemotherapy, radiation therapy, and targeted therapies such as tyrosine kinase inhibitors (TKIs). Access to the latest technologies and treatments, including innovative drugs and cutting-edge diagnostic and therapeutic tools, which can improve patient outcomes are making hospitals a go-to option for patients suffering frm GIST.
Moreover, strict quality and safety standards ensure that patients receive high-quality care and are protected from medical errors. In addition, hospitals offer the convenience of having all necessary diagnostic and therapeutic services in one location, reducing the need for multiple trips to different healthcare providers. Thus, hospitals are expected to procure 45% market share for GIST therapeutics market in 2023.
Key players in the gastrointestinal stromal tumor (GIST) therapeutics market are Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc, Cogent Biosciences, Inc, Plexxikon Inc, Theseus Pharmaceuticals, Exelixis, Inc, Ipse, Bristol-Myers Squibb and Takeda
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 890 Million |
| Market Value in 2033 | USD 1593 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Type, Therapy, End User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; MEA |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, United kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa |
| Key Companies Profiled | Arog Pharmaceuticals; Taiho Pharmaceutical; Turning Point Therapeutics, Inc.; Cogent Biosciences, Inc.; Plexxikon Inc.; Theseus Pharmaceuticals; Exelixis, Inc.; Ipsen; Bristol-Myers Squibb; Takeda |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Therapy, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End-user , 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End-user , 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033
Figure 17: Global Market Attractiveness by Drug Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Therapy, 2023 to 2033
Figure 19: Global Market Attractiveness by End-user , 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End-user , 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End-user , 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033
Figure 37: North America Market Attractiveness by Drug Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Therapy, 2023 to 2033
Figure 39: North America Market Attractiveness by End-user , 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End-user , 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End-user , 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033
Figure 57: Latin America Market Attractiveness by Drug Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Therapy, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End-user , 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by End-user , 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by End-user , 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033
Figure 77: Europe Market Attractiveness by Drug Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Therapy, 2023 to 2033
Figure 79: Europe Market Attractiveness by End-user , 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by End-user , 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by End-user , 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033
Figure 97: South Asia Market Attractiveness by Drug Type, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Therapy, 2023 to 2033
Figure 99: South Asia Market Attractiveness by End-user , 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by End-user , 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by End-user , 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033
Figure 117: East Asia Market Attractiveness by Drug Type, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Therapy, 2023 to 2033
Figure 119: East Asia Market Attractiveness by End-user , 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by End-user , 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by End-user , 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033
Figure 137: Oceania Market Attractiveness by Drug Type, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Therapy, 2023 to 2033
Figure 139: Oceania Market Attractiveness by End-user , 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Drug Type, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Therapy, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by End-user , 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Therapy, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by End-user , 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033
Figure 157: MEA Market Attractiveness by Drug Type, 2023 to 2033
Figure 158: MEA Market Attractiveness by Therapy, 2023 to 2033
Figure 159: MEA Market Attractiveness by End-user , 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
The hospital segment holds high revenue potential.
The United States and China are estimated to dominate the global market.
The market is forecast to register a CAGR of 6% through 2033.
During 2018 to 2022, the market registered a CAGR of 3.5%.
The adoption of chemotherapy treatment disrupts the current market trends.
Explore Similar Insights
Gastrointestinal Stromal Tumor (GIST) Therapeutics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
